Blood biomarkers including RF, anti−cyclic citrullinated peptide antibodies (ACPA), antistreptolysin O (ASO), ESR, and CRP have shown good performance in discriminating among a portion of typical RA patients and predicting rapid progression [38,39,40]. This evidence concerns the gene PRTN3 and rheumatoid arthritis.